BBIO BridgeBio Pharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BBIO

Price (delayed)

$26.37

Market cap

$4.28B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.75

Enterprise value

$5.7B

BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in ...

Highlights
The gross profit has plunged by 96% YoY and by 96% from the previous quarter
BridgeBio Pharma's revenue has plunged by 94% YoY and by 93% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://bridgebio.com
Peers: OGN

Key stats

What are the main financial stats of BBIO
Market
Shares outstanding
162.47M
Market cap
$4.28B
Enterprise value
$5.7B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
745.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,003.64
Earnings
Revenue
$5.68M
EBIT
-$492.46M
EBITDA
-$478.68M
Free cash flow
-$488.08M
Per share
EPS
-$3.75
Free cash flow per share
-$3.04
Book value per share
-$8.49
Revenue per share
$0.04
TBVPS
$2.97
Balance sheet
Total assets
$503.66M
Total liabilities
$1.85B
Debt
$1.73B
Equity
-$1.36B
Working capital
$322.76M
Liquidity
Debt to equity
-1.27
Current ratio
3.93
Quick ratio
3.74
Net debt/EBITDA
-2.95
Margins
EBITDA margin
-8,435%
Gross margin
53.6%
Net margin
-10,096.7%
Operating margin
-9,350%
Efficiency
Return on assets
-92.4%
Return on equity
N/A
Return on invested capital
-27.5%
Return on capital employed
-125.1%
Return on sales
-8,677.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BBIO stock price

How has the BridgeBio Pharma stock price performed over time
Intraday
-2.8%
1 week
-3.3%
1 month
-13.6%
1 year
158.53%
YTD
246.06%
QTD
53.31%

Financial performance

How have BridgeBio Pharma's revenue and profit performed over time
Revenue
$5.68M
Gross profit
$3.04M
Operating income
-$530.61M
Net income
-$572.99M
Gross margin
53.6%
Net margin
-10,096.7%
The gross profit has plunged by 96% YoY and by 96% from the previous quarter
BridgeBio Pharma's revenue has plunged by 94% YoY and by 93% from the previous quarter
BridgeBio Pharma's gross margin has decreased by 44% from the previous quarter and by 43% YoY
BBIO's net income is down by 35% since the previous quarter and by 12% year-on-year

Growth

What is BridgeBio Pharma's growth rate over time

Valuation

What is BridgeBio Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
745.96
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,003.64
BBIO's EPS is down by 32% since the previous quarter and by 7% year-on-year
BBIO's equity is down by 33% year-on-year and by 11% since the previous quarter
BridgeBio Pharma's revenue has plunged by 94% YoY and by 93% from the previous quarter

Efficiency

How efficient is BridgeBio Pharma business performance
The ROA has plunged by 57% YoY and by 54% from the previous quarter
The ROIC has contracted by 46% from the previous quarter and by 24% YoY

Dividends

What is BBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BBIO.

Financial health

How did BridgeBio Pharma financials performed over time
BBIO's total assets is 73% smaller than its total liabilities
BBIO's total assets is down by 42% year-on-year and by 20% since the previous quarter
BridgeBio Pharma's quick ratio has decreased by 32% from the previous quarter and by 28% YoY
BBIO's equity is down by 33% year-on-year and by 11% since the previous quarter
BBIO's debt to equity is up by 24% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.